I'm thrilled to announce that I will be presenting at the upcoming 5th Annual Cell & Gene Therapy World Asia, live streaming on 15th and 16th September 2021.
I will be presenting on "Foreign company pursuit of cell therapy commercialization in Japan: strategies and considerations" at 9:30AM (Singapore Time) on 16th September.
My presentation will cover the following topics:
· Unique constraints and opportunity for regenerative medicine in Japan
· Practical strategies for building a virtual team to support real progress
· PMDA conditional approval -- not the only expedited commercialization pathway in Japan
In preparing for this presentation, I had opportunity to speak with Gladys Koh of IMAPAC to discuss
1. key trends shaping the cell therapy industry moving forward in a post-pandemic world in Asia
2. exciting technologies or developments that have caught my attention in the past year
3. thoughts on how regulations pertaining to cell therapies can be evolved to allow the progress of the industry
4. current struggles with respect to commercialization of cell therapies and how would they might be overcome
5. key challenges this industry faces and is currently trying to overcome
6. developments should the industry look out for from RepliCel Life Sciences Inc. in the coming year
8. some of the key takeaways the audience can expect from my presentation
To view the interview, https://youtu.be/p2oZPbgFkMQ
Click here and here for a written advance peak at a few thoughts from some of the following speakers involved in the event such as:
Gregory Fiore, President & CEO, Exacis Biotherapeutics, USA
Zhimei Du, Global Head Process Cell Sciences, Cell/Gene Therapy, Merck & Co, USA
William Hung, Assistant General Manager, MariaVon, Taiwan
Hardy TS Kagimoto, Chairman & CEO, Healios, Japan
Pascal Touchon, President & CEO, Atara Biotherapeutics, USA
Joy (Shuxia) Zhou, Head of Drug Product Development, Cell Therapy, Takeda, USA
Magali Taiel, Chief Medical Officer, GenSight Biologics, France
Andreas Weiler, Global Head of External Supply Cell & Gene Therapy, Novartis, Switzerland
Seong-Wook Lee, President & CEO, Rznomics Inc., Korea
Yu Zhang, SVP & Chief Scientific Officer, VCANBIO Cell & Gene Engineering, China
Shi-Jiang (John) Lu, President and CEO, HebeCell Corporation
Devyn Smith, CEO, Arbor Biotechnologies, USA
Lee Buckler, President & CEO, RepliCel Life Sciences Inc.
